Serious adverse events such as purpura and dermatitis were observed in 5% of them, with a 55-year-old male patient developing exfoliative dermatitis 14 days after using the medication, albeit without fever.4 In the 1940s, several cases of lymphadenopathy associated with the use of anticonvulsants were described, the first of them accompanied by intense skin rash and fever, due to the use of diphenylhydantoin.5 The first fatality with this type of reaction was described in 1946, after the use of tridione, associated with phenylhydantoin, in an adolescent.6 The primacy of observing a case without skin rash, although with a variety of symptoms and signs of DRESS syndrome and peripheral eosinophilia, fell to Saltztein et al., in 1958, who described a boy, aged seven, who used ethylphenylhydantoin
Ipamorelin is one of them
This scenario could potentially lead to chemoresistance, diminishing the effectiveness of conventional cancer treatments
After one month of micro-dosing a GLP I noticed significant inflamation reduction
While much research has focused on the activation of stress response pathways during metabolic challenge, the mechanisms by which these pathways are attenuated once the stress subsides remain largely unexplored